RGS2在乳腺非特殊型浸润性癌组织中的表达及临床意义
发布时间：2018-07-17 15:36
【摘要】：目的:RGS2的表达改变参与了许多恶性肿瘤的发生与发展。但是,RGS2表达改变与乳腺非特殊类型浸润性癌之间的关系却不是很清楚。因此,本研究将探讨乳腺非特殊类型浸润性癌中RGS2表达情况及其与临床病理特征之间的关系,从而试图探寻一个判断乳腺癌患者预后及临床诊断相关的新指标。方法:1.筛选出2011年重庆医科大学分子检测中心中196例BIC-NST标本,应用免疫组化的方法,检测所有筛选出的BIC-NST标本中RGS2蛋白的表达量及分布情况,并将其与一些临床病理参数的相关性进行分析。2.应用数据挖掘的方法,在TCGA数据库中筛选出513例BIC-NST数据,并分析其RGS2 m RNA的表达情况与临床病理参数之间相关性。3.应用基因富集分析的方法,对TCGA数据库中筛选出的513例乳腺癌数据进行生物学功能分析。结果:1.与正常乳腺组织相比,RGS2的m RNA和蛋白表达水平在BIC-NST中都明显降低,且具有显著统计学差异(P0.001)2.低表达的RGS2蛋白水平与较差的组织学分化(P=0.006),ER阳性表达(P=0.003),PR阳性表达(P=0.024),大于2cm的肿瘤体积(P=0.002)具有相关性。3.RGS2基因的低表达水平与较大的年龄(P=0.006),ER阳性表达(P0.001),PR阴性表达(P0.001),淋巴结的阳性转移情况(P=0.011),TNM分期(P=0.020)具有相关性。4.RGS2的低表达水平与BIC-NST患者差预后相关(蛋白水平P=0.019,基因水平P=0.002),且可以成为BIC-NST患者预后不良的独立因素(蛋白水平HR=4.602,95%CI=1.467-14.432,P=0.009;基因水平HR=2.299,95%CI=1.036-5.099,P=0.041)。5.通过基因富集分析发现,RGS2 m RNA水平的低表达与乳腺癌雌激素α受体上调基因组(nominal P value=0.002,false discovery rate q value=0.1435)和luminal B型乳腺癌基因组(nominal P value=0.0,false discovery rate q value=0.1295)相关,RGS2 m RNA水平的高表达与细胞增殖负调控(nominal P value=0.0,false discovery rate q value=0.2224)和生长进程负调控(nominal P value=0.0,false discovery rate q value=0.2326)相关结论:首先,本研究的一系列结果提示RGS2可能与BIC-NST的抑癌基因相关,并且RGS2可能成为临床判断BIC-NST患者预后和辅助临床病理诊断的有用指标。最后,本研究的流程方案很有可能成为今后大数据回顾性研究的研究趋势。
[Abstract]:Objective the change of RGS2 expression is involved in the occurrence and development of many malignant tumors. However, the relationship between changes in RGS2 expression and non-specific types of invasive breast cancer is not clear. Therefore, this study will explore the expression of RGS2 and its relationship with clinicopathological features in non-special types of breast cancer, in order to explore a new indicator for the prognosis and clinical diagnosis of breast cancer. Method 1: 1. 196 BIC-NST samples from molecular detection center of Chongqing Medical University in 2011 were screened. The expression and distribution of RGS2 protein in all selected BIC-NST samples were detected by immunohistochemical method. The correlation between it and some clinicopathological parameters was analyzed. 2. 2. 513 BIC-NST data were screened from TCGA database by data mining, and the correlation between RGS2 mRNA expression and clinicopathological parameters was analyzed. The biological function of 513 breast cancer data selected from TCGA database was analyzed by gene enrichment analysis. The result is 1: 1. The mRNA and protein expression of RGS2 in BIC-NST was significantly lower than that in normal breast tissues (P0.001). The low expression level of RGS2 protein and the poor histological differentiation (P0. 006) of ER positive expression (P0. 003) positive expression of PR (P0. 024), larger than the tumor volume of 2cm (P0. 002) have a correlation. 3. The low expression level of RGS2 gene and the age (P0. 006) of ER positive expression (P0. 001) PR negative expression (P0. 001), lymphocytic cell negative expression (P0. 001). The low expression level of RGS2 was correlated with the poor prognosis of BIC-NST patients (protein level P0. 019, gene level P0. 002), and could be an independent factor of poor prognosis in BIC-NST patients (protein level HR4. 602 ~ 95CII 1.467-14. 432P0. 009; gene level HR2. 299 / 95CII 1.036-5.099P0.041). By gene enrichment analysis, it was found that the low expression of RGS2 mRNA was associated with the high expression of RGS2 mRNA in breast cancer associated with estrogen 伪 receptor up-regulated discovery rate q value=0.1435 (nominal P value0. 002 false discovery rate q value=0.1435) and luminal B breast cancer genome (nominal P value0. 0false discovery rate q value=0.1295). Conclusions: nominal P value0. 0. 0. 0. 0. 0. 0. Discovery rate q value=0.2326 discovery rate q value=0.2224 and nominal P value 0. 0. 0. 0. 0 discovery rate q value=0.2326. A series of results suggest that RGS2 may be associated with the tumor suppressor gene of BIC-NST, and RGS2 may be a useful marker for clinical prognosis and clinicopathologic diagnosis of BIC-NST patients. Finally, the flow scheme of this study is likely to be the research trend of big data retrospective research in the future.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
本文编号：2130122
[Abstract]:Objective the change of RGS2 expression is involved in the occurrence and development of many malignant tumors. However, the relationship between changes in RGS2 expression and non-specific types of invasive breast cancer is not clear. Therefore, this study will explore the expression of RGS2 and its relationship with clinicopathological features in non-special types of breast cancer, in order to explore a new indicator for the prognosis and clinical diagnosis of breast cancer. Method 1: 1. 196 BIC-NST samples from molecular detection center of Chongqing Medical University in 2011 were screened. The expression and distribution of RGS2 protein in all selected BIC-NST samples were detected by immunohistochemical method. The correlation between it and some clinicopathological parameters was analyzed. 2. 2. 513 BIC-NST data were screened from TCGA database by data mining, and the correlation between RGS2 mRNA expression and clinicopathological parameters was analyzed. The biological function of 513 breast cancer data selected from TCGA database was analyzed by gene enrichment analysis. The result is 1: 1. The mRNA and protein expression of RGS2 in BIC-NST was significantly lower than that in normal breast tissues (P0.001). The low expression level of RGS2 protein and the poor histological differentiation (P0. 006) of ER positive expression (P0. 003) positive expression of PR (P0. 024), larger than the tumor volume of 2cm (P0. 002) have a correlation. 3. The low expression level of RGS2 gene and the age (P0. 006) of ER positive expression (P0. 001) PR negative expression (P0. 001), lymphocytic cell negative expression (P0. 001). The low expression level of RGS2 was correlated with the poor prognosis of BIC-NST patients (protein level P0. 019, gene level P0. 002), and could be an independent factor of poor prognosis in BIC-NST patients (protein level HR4. 602 ~ 95CII 1.467-14. 432P0. 009; gene level HR2. 299 / 95CII 1.036-5.099P0.041). By gene enrichment analysis, it was found that the low expression of RGS2 mRNA was associated with the high expression of RGS2 mRNA in breast cancer associated with estrogen 伪 receptor up-regulated discovery rate q value=0.1435 (nominal P value0. 002 false discovery rate q value=0.1435) and luminal B breast cancer genome (nominal P value0. 0false discovery rate q value=0.1295). Conclusions: nominal P value0. 0. 0. 0. 0. 0. 0. Discovery rate q value=0.2326 discovery rate q value=0.2224 and nominal P value 0. 0. 0. 0. 0 discovery rate q value=0.2326. A series of results suggest that RGS2 may be associated with the tumor suppressor gene of BIC-NST, and RGS2 may be a useful marker for clinical prognosis and clinicopathologic diagnosis of BIC-NST patients. Finally, the flow scheme of this study is likely to be the research trend of big data retrospective research in the future.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
【参考文献】
相关期刊论文 前1条
1 ;Chromosomal aberrations related to metastasis of human solid tumors[J];World Journal of Gastroenterology;2002年05期
，本文编号：2130122
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2130122.html
